As such, the reductions of 5HT and melatonin, which influence mood and have broader consequences on clinical progression in MS, can be recognised as a secondary consequence of KP activation that can be induced through the shared inflammatory mediators in depression and MS. The gene discussed is NPPA; the disease is myeloid sarcoma.